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628Objective: We sought to review the surgical outcomes of our initial 120 robotic mitral valve repairs from June
2005 through April 2009.
Methods: The initial 74 repairs were performed with the first-generation da Vinci robot (Intuitive Surgical, Inc,
Sunny Vale, Calif), and the last 46 were performed with the da Vinci Si HD model. All patients received an an-
nuloplasty band and 1 or more of the following: leaflet resection; annuloplasty; basal chord transposition, poly-
tetrafluoroethylene neochordal replacement, or both; and edge-to-edge repair.
Results: The overall mean age was 58.4  10.5 years, and 64% were male. There was 1 (0.8%) hospital mor-
tality. Five patients required mitral valve replacement for a failed repair. Another patient had mitral valve rerepair
on postoperative day 2. Except for 2 early reoperations for postoperative bleeding, all of the complications and
failed repairs requiring operative revision occurred with the original robot. Postdischarge transthoracic echocar-
diographic follow-up was available on 107 (93%) of 115 patients, with a median follow-up of 321 days. None to
mild mitral regurgitation was seen in 102 (89%) patients, moderate mitral regurgitation was seen in 9 (8.4%)
patients, and severe mitral regurgitation was seen in 3 (2.8%), with 1 patient undergoing mitral valve replacement
and 2 patients being medically managed.
Conclusions: The majority of complications and all the repeat operations for failed mitral valve repair occurred
with the older-model da Vinci robot. The newer da Vinci Si HD system, with the addition of an adjustable left
atrial roof retractor, improves mitral valve exposure, enhancing the surgeon’s ability to repair and test the valve.
We have progressed to successful repair of all types of degenerative mitral valve pathology and have found the
approach reproducible. (J Thorac Cardiovasc Surg 2010;139:628-33)Since Dr Carpentier’s introduction of the ‘‘French correc-
tion,’’ mitral valve repair for degenerative (myxomatous)
disease has become the gold standard approach.1 In the
mid-1990s, several surgical groups developed and refined
techniques with small thoracotomy endoscopic approaches,
achieving results equal to those seen with the traditional ster-
notomy operation.2-4 Dr Chitwood further refined the endo-
scopic approach, taking advantage of the da Vinci Robotic
Surgical System (Intuitive Surgical, Inc, Sunny Vale, Calif)
and its advanced robotic technology to repair complex mitral
valve pathology.5-7 The excellent clinical outcome was built
on the foundation of stepwise improvement in technique
with a gradual learning curve.7,8
In 2005, we embarked on the process of developing a ro-
botic mitral valve surgery program. We had a small experi-e Division of Cardiothoracic Surgery, Cedars–Sinai Medical Center, Los
les, Calif.
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The Journal of Thoracic and Cardiovascular Surgence with a right minithoracotomy for mitral surgery. Our
team’s orientation and training included programmatic and
simulation training at the surgical Robotic Training Center
at East Carolina University and visits to other high-volume
centers to observe robotic mitral surgery cases. On-site proc-
toring by Intuitive Surgical, Inc, for our initial cases supple-
mented the training we received. This report describes the
clinical outcomes in our first 120 patients undergoing ro-
bot-assisted mitral valve repair.MATERIALS AND METHODS
From June 2005 through April 2009, 120 patients underwent intent-to-
treat endoscopic robotic mitral valve repair. There was 1 intraoperative con-
version to a right minithoracotomy before completion of the mitral repair.
This was due to external instrument conflicts of the robotic arms that could
not be resolved because of the space limitations of working in a small right
hemithorax. Otherwise, 119 patients achieved successful completion of the
robotic mitral valve repair. Robotic mitral valve repair represents an increas-
ing proportion of a single surgeon’s (AT) experience with various ap-
proaches, minithoracotomy, and sternotomy during this period (Figure 1).
Patients with heavily calcified mitral valve annuli, dense right pleural ad-
hesions, and severe aortoiliac atherosclerosis were approached through
a median sternotomy. Patients with prior median sternotomy were ap-
proached through a minithoracotomy or redo median sternotomy. Patients
likely to require mitral valve replacement, such as those with rheumatic mi-
tral disease, endocarditis, and restrictive posterior leaflet pathology, tended
to be approached through a minithoracotomy or median sternotomy.
The data presented in this retrospective review were obtained from an in-
stitutionally supported Cardiothoracic Surgery Quality Assurance Database.
The study was approved by the Cedars–Sinai Institutional Review Boardery c March 2010
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FIGURE 1. The bar graph shows the trends in the surgical approach used
for mitral valve repair surgery at our institution from 2002 to the present.
Abbreviations and Acronyms
MR ¼ mitral regurgitation
SAM ¼ systolic anterior motion
TEE ¼ transesophageal echocardiography
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on the patients and given that it would not adversely affect the rights and
welfare of these patients who were deidentified for this group analysis.
Operative Technique
Our current standard practice is to intubate the patient with a double-lu-
men endotracheal tube and place a coronary sinus cardioplegia catheter dur-
ing transesophageal echocardiographic (TEE) guidance. In our early
experience, contrast dye was injected to check the catheter position during
fluoroscopic analysis. In addition, a pulmonary artery drain was placed for
left heart drainage. Both of these techniques were later believed to be unnec-
essary and discontinued. With TEE guidance, more than 90% of patients
have had successful placement of a coronary sinus catheter for retrograde
cardioplegia delivery. There were no instances of coronary sinus damage
or rupture from either catheter placement or use.
After the patient is positioned supine with the right side of the chest el-
evated, the right lung is deflated, and a 3- to 4-cm right inframammary in-
cision through the fourth or fifth intercostal space is made as the working
port. Trocars for the robotic instrument arms, 14-gauge angiocatheters for
traction sutures, and a 20F DLP (Medtronic, Inc, Minneapolis, Minn) intra-
cardiac sump drain are inserted through a separate stab-wound incision. Our
first 74 cases were performed with the original version of the da Vinci Ro-
botic Surgical System. For these first cases, the handle of the atrial septal
roof retractor (Cardiovations, Irvine, Calif) was inserted just lateral to the
right intrathoracic artery. The last 46 cases were performed with the sec-
ond-generation da Vinci Si HD, with a fourth articulating arm as a movable
left atrial roof retractor.
The patient is heparinized and the femoral vessels are cannulated for car-
diopulmonary bypass. A 2-stage venous cannula is placed through the fem-
oral vein under TEE guidance to ensure proper placement for venous
drainage with vacuum assistance.
The pericardium is incised ventral to the phrenic nerve. A transthoracic
aortic clamp (Scanlan International, Minneapolis, Minn) is positioned
through the third intercostal space in the midaxillary line. An ascending aor-
tic root vent (DLP 14-gauage 7F; Medtronic, Inc) is placed under direct vi-
sion. The da Vinci robot is positioned to the patient’s left side, and the
instrument arms are placed endoscopically. Bypass is established, and the
patient is cooled to 32C. Once cold, the crossclamp is positioned and
clamped under endoscopic vision. One hundred twenty milliliters of cold
blood cardioplegia (Kþ, mannitol, HCO3 mixture) is infused directly
through the aortic root. Then retrograde crystalloid cardioplegia is gravity
dripped into the coronary sinus catheter limited to 1 L per patient. If the cor-
onary sinus catheter could not be placed or becomes dislodged, multiple
200-mL doses of cold antegrade crystalloid cardioplegia would be adminis-
tered by the anesthesiologist about every 20 minutes after crossclamping to
supplement the initial dose of cold blood cardioplegia. Once asystole is
achieved, a standard left interatrial incision is made with the robot, and
the left atrial roof retractor is positioned for mitral valve exposure.
If a concomitant CryoMaze procedure is performed, the Cryocath (Med-
tronic CryoCath LP, Montreal, Quebec, Canada) is used to create a pulmo-
nary vein isolation box lesion and a connecting lesion to the mitral annulus.
Then standard mitral repair techniques are used for leaflet resections and re-
constructions with suture knot tying done intracorporeally with the robotic
arms. If polytetrafluoroethylene neochordae (Gore–Tex suture; W. L. Gore
and Associates, Inc, Flagstaff, Ariz) are placed, knot tying is done extracor-The Journal of Thoracic and Caporeally by the bedside assistant surgeon using a shafted knot pusher. All of
the annuloplasty bands used were partial rings. Initially, we used the Tailor
band (St Jude Medical, Inc, St Paul, Minn) but later switched to the ATS
band (ATS Medical, Inc, Minneapolis, Minn) because it crimped less
when secured with either of 2 techniques: nitinol U-clips (Medtronic, Inc)
or 2–0 Cardioflon sutures (Peters, Inc, Paris, France). Left atriotomy closure
is done with a running 4–0 polytetrafluoroethylene sutures. Deairing the
heart is performed with active suction on the aortic root vent with increasing
controlled ejection while at the same time actively ventilating and decreas-
ing pump flow. The completeness of deairing is monitored by using TEE.
Humidified CO2 is also insufflated into the operative field through the cam-
era port.
Follow-up
All surviving patients (n¼ 119) were examined and clinically evaluated
within 2 weeks after hospital discharge. Further clinical follow-up was ob-
tained through direct patient contact or through the patients’ referring phy-
sicians. Echocardiographic follow-up reports are routinely obtained from
the referring physicians. Median echocardiographic follow-up was 321
days (mean  standard deviation, 372.9  331.6 days).
Statistical Methods
Numeric variables are summarized as means  standard deviations or
medians (ranges). Categorical variables are summarized as frequencies (per-
centages).
Patient Characteristics
Table 1 lists the preoperative patient characteristics. All patients under-
went functional valve assessment by means of intraoperative TEE, and the
valve pathology is confirmed at the time of the operation (Table 2).
RESULTS
Table 3 lists the operative details of all 120 patients. All
patients received an annuloplasty band. Five patients re-
ceived only a simple band. One third (40 [33.3%]) of the
patients had a leaflet resection and annuloplasty. There
were 40 patients who had chordal procedures, either the
transfer of basal chords (n ¼ 12) or implantation of polyte-
trafluoroethylene chords (n ¼ 28).
Two patients were converted to mitral valve replacement
at the time of the initial operation for failed repairs. Patient
33 had posterior leaflet restriction after repair and proceeded
to porcine valve replacement through a median sternotomy.rdiovascular Surgery c Volume 139, Number 3 629
TABLE 1. Preoperative demographics
Characteristics
Age (y), mean  SD 58.4  10.5
Age (y), range 33–86
Sex
Male 77 (64.2)
Female 43 (35.8)
Body mass index (kg/km2), mean  SD 25.4  4.0
Body mass index, range 18.8–37.3
New York Heart Association class
I 26 (21.7)
II 43 (35.8)
III 45 (37.5)
IV 6 (5.0)
Comorbidities
Congestive heart failure 94 (78.3)
Diabetes 3 (2.5)
Hypertension 37 (30.8)
Serum creatinine>2.0 mg/dL 0 (0)
Atrial fibrillation/flutter 29 (24.2)
Stroke 0 (0)
Transient ischemic attack 4 (3.3)
Peripheral vascular disease 2 (1.7)
Smoking history 30 (25.0)
Previous cardiac surgery 1 (0.8)
Echocardiographic findings
LV ejection fraction, mean  SD 61.2%  7.7%
LV ejection fraction, range 38%–86%
Severe mitral regurgitation 120 (100)
Values are presented as numbers (percentages), unless indicated otherwise. SD, Stan-
dard deviation; LV, left ventricular.
TABLE 3. Operative characteristics
Mitral valve repair type
Annuloplasty band 120 (100)
Band size (mm), median (range) 33 (23–39)
Annuloplasty band alone 5 (4.2)
Edge-to-edge 7 (5.8)
Edge-to-edgeþchordal procedure 4 (3.3)
Leaflet resection 28 (23.3)
Leaflet resectionþannuloplasty 40 (33.3)
Leaflet resectionþchordal procedure  annuloplasty 16 (13.3)
Chordal procedure (no leaflet resection) 20 (16.7)
Polytetrafluoroethylene neochordae 28 (23.3)
Concomitant procedures
CryoMaze atrial fibrillation ablation 29 (24.2)
Exclusion of left atrial appendage 15 (12.5)
Atrial septal defect closure 1 (0.8)
Patent foramen ovale closure 8 (6.7)
Perfusion details
Cardiopulmonary bypass time (min), mean  SD 156.9  43.5
Crossclamp time (min), mean  SD 116.6  30.6
Values are presented as numbers (percentages), unless indicated otherwise. SD, Stan-
dard deviation.
Acquired Cardiovascular Disease Cheng et al
A
C
DPatient 68 had a failed repair of a Barlow valve caused by
postrepair left ventricular outflow obstruction associated
with systolic anterior motion (SAM) of the mitral valve
and had placement of a porcine valve through the minithor-
acotomy incision.
One quarter (29 [24.2%]) of the patients had a concomi-
tant left-sided CryoMaze procedure, with 15 (12.5%)
having left atrial appendage exclusion with a running 4–0
polytetrafluoroethylene suture. Eight (6.7%) patients hadTABLE 2. Echocardiographic and operative mitral valve characteristics
(n ¼ 120)
Carpentier classification
Type 1 5 (4.2)
Type 2 115 (95.8)
Anterior prolapse 7 (5.8)
Posterior prolapse 86 (71.7)
Bileaflet prolapse 22 (18.3)
Type 3 0 (0)
Valve pathology
Degenerative
Fibroelastic deficiency 106 (88.3)
Barlow 6 (5.0)
Endocarditis 8 (6.7)
Values are presented as numbers (percentages).
630 The Journal of Thoracic and Cardiovascular Surgpatent foramen ovale closure, and 1 had an atrial septal de-
fect closure. The mean crossclamp time was 116.6  30.6
minutes. There were 41 patients with crossclamp times of
greater than 120 minutes, and 5 patients with crossclamp
times of greater than 180 minutes. The longest crossclamp
time was 221 minutes, and this patient represented the
only surgical death in the series. Patients with prolonged
crossclamp times had more complex procedures, often
with an associated CryoMaze procedure. There were 2 repair
failures requiring subsequent valve replacement in these 41
patients. Of the remaining 38 patients, all are asymptomatic
and in New York Heart Association class I. We are currently
following 1 patient with recurrent severe mitral regurgitation
(MR) and 1 patient with moderate MR.
Mortality and Morbidity
Postoperative complications are listed in Table 4. There
was 1 (0.8%) early death, and this occurred in patient 4,
who had severe myocardial dysfunction after repair. Despite
ECMO followed by conversion to biventricular assist device
support, the patient died on postoperative day 3 from multi-
system organ dysfunction. The final pathology report con-
firmed a massive left ventricular hemorrhagic infarction. In
our first 4 patients, we did not place a coronary sinus catheter
for retrograde cardioplegia delivery. Our myocardial protec-
tion consisted of 120 mL of antegrade cardioplegia followed
by 1 L of cold crystalloid cardioplegia. The patient had bi-
leaflet prolapse requiring a posterior leaflet resection and
transposition of 4 sets of basal chords to the anterior leaflet.
This took 221 minutes of crossclamp time. Despite no obvi-
ous electrical activity on the monitor during the period of
crossclamping, it is very likely that the myocardial protec-
tion was not sufficient.ery c March 2010
TABLE 4. Postoperative outcomes and complications
30-d Mortality 1 (0.8)
Late mortality 0 (0)
Myocardial infarction 1 (0.8)
Stroke 2 (1.7)
Reversible neurologic injury 2 (1.7)
Prolonged mechanical ventilation (>48 h) 2 (1.7)
Bleeding requiring reoperation 6 (5.0)
Any blood product transfusion 45 (37.5)
pRBC 23 (19.1)
FFP 32 (26.7)
Platelets 36 (30.0)
Infection 0 (0)
Serum creatinine>2.0 mg/dL 3 (2.5)
Atrial fibrillation/flutter 12 (10.0)
Pleural effusion 2 (1.7)
Diaphragm paralysis 1 (0.8)
Needle lost in left inferior pulmonary vein 1 (0.8)
Hospital length of stay (d), mean  SD 6.3  3.9
Readmission within 30 d 1 (0.8)
Repair failures and second operation
Mitral replacement through sternotomy 4 (3.3)
Mitral valve replacement through minithoracotomy 1 (0.8)
Mitral valve rerepair through minithoracotomy 1 (0.8)
Values are presented as numbers (percentages), unless indicated otherwise. pRBC,
Packed red blood cells; FFP, fresh frozen plasma; SD, standard deviation
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strategy to include coronary sinus catheter placement for de-
livery of cold retrograde crystalloid cardioplegia, up to 1 L
total, administered by means of continuous drip. We cur-
rently use multiple doses of cold antegrade crystalloid cardi-
oplegia every 20 minutes when retrograde access for
cardioplegia delivery is not available. Of the first 3 patients
who received only 120 mL of antegrade blood cardioplegia
followed by 1 L of crystalloid cardioplegia as an initial dose,
all are doing well at 4 years’ follow-up, with ejection frac-
tions of 55% to 62% and no more than trace MR at the latest
follow-up. More than 90% of patients subsequently had
retrograde cardioplegia or multiple doses of antegrade
crystalloid cardioplegia, with no problems encountered in
myocardial protection since the change.
There was no late mortality in this series. Patient 39 had
a small, less than 1-cm laceration to the dome of the dia-
phragm through the roof of the liver. This led to abdominal
bleeding (heparinized), which was noted after the mitral re-
pair was completed. Themitral repair was intact, but he expe-
rienced cardiac arrest after protamine had been administered
and required a laparotomy to repair the liver laceration. He
has a permanent right hemisphere strokewithmoderate resid-
ual disability. It is likely that the diaphragm laceration and
liver injury occurred with placement of the robotic arms.
Overall, there were 2 patients with strokes who have per-
sistent neurologic deficits, and 2 (1.7%) patients experi-
enced a transient neurologic event with full resolution. Six
(5.0%) patients returned to the operating room for postsur-The Journal of Thoracic and Cagical bleeding or for evacuation of retained hemothorax
during their initial hospital stay. Three patients had postop-
erative creatinine values of greater than 2.0 during their
hospitalization, with 1 patient requiring temporary hemodi-
alysis. There were no femoral artery or vein complications
and no lymphoceles requiring surgical intervention. The
hospital length of stay was 6.3  3.9 days, with only
1 (0.8%) patient requiring readmission within 30 days.
In addition to the 2 patients converted to mitral valve re-
placement at the time of the initial failed robotic mitral valve
repairs, there have been 3 subsequent operations for early
(<30 day) repair failure, with 2 (1.7%) mitral valve replace-
ments and 1 (0.8%) repeat repair through aminithoracotomy.
All of these repair failures occurred in the first 74 patients
who underwent repair with the older-model da Vinci robot.
Since the introduction of the da Vinci Si HD, there have
been nomajor complications, with only 2 (1.7%) patients re-
turning to the operating room for postoperative bleeding.
Echocardiographic Studies and Patient Follow-up
All 120 patients had severe MR, as determined by means
of preoperative transthoracic echocardiographic analysis
(Table 5) that was confirmed with prepump TEE. There
were 2 patients with moderately severe MR, as determined
by postpump TEE, who then had the valve replaced. Four
additional patients had moderate-to-severe MR during the
hospitalization.
Patient 25 underwent rerepair of the mitral valve through
the original minithoracotomy incision. At the time of the op-
eration, the band and part of the posterior leaflet were par-
tially dehisced from the mitral annulus. This band
dehiscence was due to placement of the nitinol clips insuffi-
ciently deep in the mitral annulus.
Patient 53 had a restricted posterior leaflet as the source of
his recurrent MR and had a mitral valve replacement through
a median sternotomy on postoperative day 3.
Patient 58 had worsening SAM that was unresponsive to
medical management and had mitral valve replacement on
postoperative day 6 through a minithoracotomy. In this pa-
tient we treated severe prolapse of the posterior leaflet (P2
and P3) with multiple polytetrafluoroethylene chords and
a 35-mm ATS band. His initial postoperative TEE showed
only trace MR, but he later developed SAM. In retrospect,
the surgeon believed he should have resected some of the
posterior leaflet to reduce its height, thereby minimizing
the chance for SAM.
Patient 5 had severe MR on predischarge transthoracic
echocardiographic analysis, which remains unchanged. He
is currently being medically managed and is asymptomatic
at 3 years’ follow-up.
Patient 47 had mitral valve replacement on day 41 per-
formed through a median sternotomy. At the time of the first
operation, he was found to have a Barlow-type valve with
bileaflet prolapse. Two polytetrafluoroethylene chordsrdiovascular Surgery c Volume 139, Number 3 631
TABLE 5. Echocardiographic data
Preoperative TTE (n ¼ 120) Postpump TEE (n ¼ 119) In-hospital TTE (n ¼ 20) Postdischarge TTE (n ¼ 107)
MR severity
None 65 (54.2) 5 (25) 35 (32.7)
Trace 33 (27.5) 7 (35) 32 (29.9)
Mild 19 (15.8) 3 (15) 28 (26.2)
Moderate 2 (1.7) 2 (10) 9 (8.4)
Severe 120 (100) 0 (0) 3 (15) 3 (2.8)
da Vinci Preoperative TTE (n ¼ 74) Postpump TEE (n ¼ 73) In-hospital TTE (n ¼ 16) Out-of-hospital TTE (n ¼ 66)
MR severity
None 36 (49.3) 4 (25) 20 (30.3)
Trace 23 (31.5) 4 (25) 18 (27.3)
Mild 12 (16.4) 4 (25) 20 (30.3)
Moderate 2 (2.7) 1 (6.2) 5 (7.6)
Severe 74 (100) 0 (0) 3 (18.8) 3 (4.5)
da Vinci Si HD Preoperative TTE (n ¼ 46) Postpump TEE (n ¼ 46) In-hospital TTE (n ¼ 5) Out-of-hospital TTE (n ¼ 41)
MR severity
None 29 (63.0) 1 (20) 15 (36.6)
Trace 10 (21.7) 3 (60) 14 (34.1)
Mild 7 (15.2) 0 (0) 8 (19.5)
Moderate 0 (0) 1 (20) 4 (9.8)
Severe 46 (100) 0 (0) 0 (0) 0 (0)
Values are presented as numbers (percentages). TTE, Transthoracic echocardiography; TEE, transesophageal echocardiography; MR, mitral regurgitation.
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let, with a triangular resection of the middle scallop of the
posterior leaflet (P2). A number 35 ATS band was placed.
Intraoperative TEE confirmed trace residual MR. The post-
pump mitral valve annular diameter was 26 mm.Myocardial
protection was with our standard 120 mL of antegrade blood
cardioplegia followed by a total of 850 mL of cold retro-
grade crystalloid cardioplegia administered by means of
continuous drip. Crossclamp time was 2 hours and 14 min-
utes with a perfusion time of 3 hours and 2 minutes. The pa-
tient required no inotropic support after the operation.
Discharge was delayed until postoperative day 9 because
of postoperative atrial fibrillation, which required warfarin
anticoagulation but no antiarrhythmic drug therapy. This pa-
tient later had unexpected cardiomyopathy after hospital dis-
charge, with an ejection fraction of 25% at the time of his
valve replacement. We do not believe myocardial protection
was a contributing factor because ventricular function was
normal after valve repair surgery and required no inotropic
support. At the time of the operation, the preoperative
TEE showed dehiscence of the band from the posterior an-
nulus when compared with the postrepair TEE from 41
days previously. The prepump mitral annular diameter was
now 37.5 mm, more than 11 mm larger than the diameter af-
ter the first repair. This was confirmed by the surgeon at re-
operation, with band dehiscence from the posterior annulus
caused by annular dilatation. We are currently following 2
additional patients with recurrent severeMRmedically man-
aged and asymptomatic at last follow-up.632 The Journal of Thoracic and Cardiovascular SurgThe 1 death and 7 failed repairs all occurred in the first 74
patients who underwent repair with the older-model da Vinci
robot that lacked the adjustable left atrial roof retractor. The
last 46 patients in this series, who underwent repair with the
da Vinci Si HD, have had no mitral valve reinterventions to
date. However, there are 4 patients in this later cohort who
we are following with moderate MR. One of these patients
had a P2 triangular resection and placement of an ATS
band. One of his follow-up echocardiograms showed mild-
to-moderate MR. He is currently asymptomatic. The other
3 patients had annular dilatation and were treated with
ATS bands. They currently have moderate MR and are
asymptomatic with medical management. Our present prac-
tice is to use a complete ring for these patients because a par-
tial ring might not provide the best annular stabilization at
different loading conditions for these patients.
DISCUSSION
Robotic mitral valve repair has been performed with ex-
cellent results by a limited number of surgeons who have
had an extensive background in minimally invasive mitral
valve surgery.4-8 In October 2000, a US Food and Drug
Administration–approved, multicenter, phase II trial
(G000295) was initiated, with 10 centers evaluating the da
Vinci surgical system. The results of this multicenter trial
were reported to the surgical community at the American
Association for Thoracic Surgery meeting in Boston in
2003. Subsequently, large clinical series with excellent clin-
ical and echocardiographic outcomes have been reported.4-8ery c March 2010
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DWe initiated our robotic mitral surgery program in 2005.
Our surgical team was initially trained at the Surgical Ro-
botic Training Center at East CarolinaUniversity using a cur-
riculum-based program that included case observation,
didactic sessions, and both inanimate and cadaver models.
Further training, sponsored by Intuitive Surgical, Inc, in-
cluded robotic case observations in Atlanta, Georgia, and
Spokane, Washington. Our initial cases were proctored by
representatives of Intuitive Surgical, Inc.
Our team’s learning curve can be separated into 2 phases.
The initial phase was the first 74 patients with the older-
model da Vinci robot that lacked the adjustable fourth artic-
ulating arm, which allows the surgeon to adjust left atrial
exposure as he or she works on different areas of the mitral
valve. The second phase was the last 46 patients with the
newer-model da Vinci Si HDwith an adjustable left atrial re-
tractor and improved 3-dimensional visualization. All of the
failed repairs requiring 5 valve replacements and 1 rerepair
occurred with the earlier-generation robot. Two additional
patients are being medically managed with severe MR. Of
the 46 patients undergoing repair with the da Vinci Si HD,
none have severe MR at the last follow-up, with 4 (9.8%)
being followed for moderate MR.
The difficulty we experienced maintaining optimal expo-
sure of the mitral valve for the entire operation led to techni-
cal difficulty with certain aspects of the valve repair,
including band placement, leaflet repair, and testing of the
valve. The da Vinci Si HD, with its adjustable atrial roof re-
tractor, provides mitral valve exposure that can be adjusted
as a surgeon works on different areas of the mitral valve.
It can be removed completely or the retraction can be de-
creased when the surgeon tests the valve repair with saline
injection. We believe that this flexibility allows more secure
and accurate placement of the stitches used for the repair.
Moreover, the surgeon has an enhanced ability to study
the valve and determine a plan for valve repair and then ac-
curately test the result. The previous da Vinci robot model
for mitral valve exposure relied on a left atrial retractor blade
connected to a metal rod placed percutaneously through the
fifth intercostal space and held with an adjustable metal arm
attached to the side rail of the operating room bed. Adjust-
ments were impossible during the course of the operation
unless the robot was repositioned away from the patient’s
left side. After the exposure was achieved, we would then
need to reposition the robot and replace the instruments
and camera. Rather than perform these time-consuming
steps, the surgeon would often proceed with less than opti-
mal visualization. We believe that the 2 instances of ring de-
hiscence were due to poorly placed annuloplasty stitches
caused by poor exposure. Having complete freedom to ad-
just our valve exposure during our later cases allowed us
to implement advanced anterior leaflet repair techniques,
such as chordal transposition and placement of polytetra-
fluoroethylene neochords. Since the introduction of the daThe Journal of Thoracic and CaVinci Si HD, there have been no repair failures, and the
echocardiographic follow-up has documented a low inci-
dence of residual or recurrent MR.
The majority of our complications occurred in our first 74
patients. Our only death occurred in patient 4, who under-
went a complicated repair with a long crossclamp time.
We relied on a single 120-mL dose of antegrade blood car-
dioplegia followed by 1 L of antegrade crystalloid cardiople-
gia. On unclamping, there was severe left ventricular
dysfunction, which did not improve and later required extra-
corporeal membrane oxygenation support.
Four strokes have occurred in this entire series, with 2 com-
pletely resolved and 2 partially resolved. We routinely evalu-
ate the thoracic aorta down to the iliac arteries with
a computed tomographic angiogram, looking for calcific vas-
cular disease that would increase the risk of retrograde femo-
ral perfusion in patients older than 70 years and in patients
younger than 70 years who have risk factors for vascular dis-
ease, such as diabetes, hypertension, and a significant smok-
ing history. Although not eliminating retrograde aortic
perfusion as a source of cerebral emboli and neurologic defi-
cits, we believe that this will minimize the risk. We insufflate
CO2 continuously through the camera introducer, flooding the
operative field with CO2 in an attempt to reduce left atrial and
ventricular air bubbles. These neurologic deficits could still be
due to inadequate deairing or retained particulate embolus
from the operative field. We are very careful with broken su-
tures and other debris encountered during the repair, ensuring
that we remove all these sources of potential embolus.
Overall, we are satisfied with our clinical outcomes after
robotic mitral valve repair. We believe that robotic mitral
valve repair since the introduction of the da Vinci Si HD,
the latest-generation robotic surgical system, has become
easier to perform and the quality of the valve repair has im-
proved. Robotic mitral valve repair has become a reproduc-
ible approach. Longer-term follow-up will be needed to
confirm the durability of our robotic mitral valve repairs.
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